Table 2.
Significant differentially expressed proteins
| No. | Proteins | Fold change | Average of normalized data (log2) | Up/down | Normalized data (log2) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AVN | CON | AVN1 | AVN2 | AVN3 | CON1 | CON2 | CON3 | ||||
| 1 | FN1 | 100 | 20.25 | . | UP | 21.04 | . | 18.42 | . | . | . |
| 2 | VWF | 3.379 | 25.35 | 22.61 | UP | 26.29 | 24.41 | 24.48 | 23.03 | 22.73 | 21.79 |
| 3 | IGHV3-23 | 100 | 21.57 | . | UP | 22.44 | . | 19.02 | . | . | . |
| 4 | FGB | 100 | 22.26 | . | UP | 22.65 | . | 21.73 | . | . | . |
| 5 | IGLV3-1 | 100 | 22.41 | . | UP | 22.41 | . | . | . | . | . |
| 6 | PRG4 | 3.827 | 19.91 | 18.23 | UP | 20.17 | 20.45 | 18.43 | 18.23 | . | . |
| 7 | PRDX1 | 3.493 | 22.25 | 20.45 | UP | 22.25 | . | . | 20.45 | . | . |
| 8 | SACS | 100 | 20.77 | . | UP | 20.77 | . | . | . | . | . |
| 9 | H2AW | 0.01 | . | 20.36 | Down | . | . | . | 20.36 | . | . |
| 10 | IGHV3-20 | 0.01 | . | 22.49 | Down | . | . | . | . | 22.49 | . |
| 11 | FCGBP | 0.43 | 21.11 | 22.26 | Down | 20.61 | 21.43 | 21.18 | 21.62 | 22.39 | 22.59 |
| 12 | DHX37 | 0.01 | . | 20.04 | Down | . | . | . | 20.04 | . | . |
| 13 | DPY19L4 | 0.339 | 22.30 | 22.34 | Down | . | 23.25 | 18.31 | . | 22.34 | . |
| 14 | ZSWIM9 | 0.409 | 23.86 | 25.08 | Down | 24.24 | 23.49 | 23.76 | 25.05 | 24.93 | 25.24 |
FN1 (fibronectin 1); VWF (von Willebrand factor); IGHV3-23 (immunoglobulin heavy variable 3–23); FGB (fibrinogen beta chain); IGLV3-1 (Immunoglobulin lambda variable 3 − 1); PRG4 (proteoglycan 4); PRDX1 (peroxiredoxin-1); SACS (spastic ataxia of Charlevoix-Saguenay); H2AW (Histone H2A type 3); IGHV3-20 (immunoglobulin heavy variable 3–20); FCGBP (Fc Gamma Binding Protein); DHX37 (DEAH-box helicase 37); DPY19L4 (dpy-19 like 4); ZSWIM9 (zinc finger SWIM-type containing 9)